NCT03210961 - A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

July 14, 2017

Primary Completion Date

January 25, 2019

Study Completion Date

January 25, 2019

Conditions

Plaque Psoriasis

Interventions

DRUG

PF-06826647 tablet

PF-06826647 tablet for oral administration

DRUG

PF-06826647 oral suspension

PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)

OTHER

Placebo oral solution/suspension

placebo oral solution for the single ascending dose, first cohort only

OTHER

Placebo tablet

Matching placebo tablet

Trial Locations (1)

Anaheim Clinical Trials, LLC, Anaheim